Nature Communications (Jul 2016)

ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer

  • Geneviève Deblois,
  • Harvey W. Smith,
  • Ingrid S. Tam,
  • Simon-Pierre Gravel,
  • Maxime Caron,
  • Paul Savage,
  • David P. Labbé,
  • Louis R. Bégin,
  • Michel L. Tremblay,
  • Morag Park,
  • Guillaume Bourque,
  • Julie St-Pierre,
  • William J. Muller,
  • Vincent Giguère

DOI
https://doi.org/10.1038/ncomms12156
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 14

Abstract

Read online

Despite initial benefits in treating HER2-positive breast cancer patients with lapatinib, resistance is prevalent. Here the authors show that lapatinib resistance can be ascribed to mTOR-mediated re-activation of ERRα and to the consequent induction of a metabolic adaptation.